MedMira Strengthens US Patent Protection with New Filings and Continued Examination



    HALIFAX, Oct. 21 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,
NASDAQ:   MMIRF), a developer and marketer of rapid diagnostics, announced today
that it is broadening its US patent portfolio with new filings related to the
Company's rapid flow-through technology, the core innovation behind its rapid
diagnostics. In order to strengthen its overall IP position, the Company has
also filed for continued examination on its original US patent application
that was allowed in July 2008.
    "We believe that our technology is one of our Company's most valuable
assets and as such we are taking further steps to strengthen the IP around it,
as we move forward with licensing and partnership opportunities. Additional IP
was identified during our review and analysis of our rapid flow-through
technology and we are now working with our external team to prepare and file
patent applications to protect it," said Dr. Neeraj Vats, VP of Technology &
Intellectual Property, MedMira Inc. "We will also be filing a Request for
Continued Examination in order to strengthen our original US patent
application, which received a Notice of Allowance from the USPTO earlier this
year."

    About MedMira

    MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics. The company's tests provide hospitals, labs, clinics and
individuals with reliable, rapid diagnosis for diseases such as HIV and
hepatitis C in just three minutes. The company's tests are sold under the
Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global
markets. MedMira's rapid HIV test is the only one in the world to achieve
regulatory approvals in Canada, the United States, China and the European
Union. MedMira's corporate offices and manufacturing facilities are located in
Halifax, Nova Scotia, Canada. For more information visit MedMira's website at
www.medmira.com.

    This news release contains forward-looking statements, which involve risk
and uncertainties and reflect the company's current expectation regarding
future events. Actual events could materially differ from those projected
herein and depend on a number of factors including, but not limited to,
changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to
time in the company quarterly filings.

    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of this statement.
    %SEDAR: 00013053E




For further information:

For further information: Dr. James Smith, Investor Relations & Corporate
Affairs, (902) 450-1588, ir@medmira.com; Andrea Young, Corporate
Communications, (902) 450-1588, media@medmira.com

Organization Profile

MedMira Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890